相关实验视频

Updated: May 21, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

在SMARCA4缺陷的晚期胸部瘤患者中,抗血管原治疗的有效性

Mengting Shi¹, Xueyuan Chen², Ting Lin³

¹Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou, Guangdong 515000, China; Shantou University Medical College, 22 Xinling Road, Shantou, Guangdong 515000, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

Lung cancer (Amsterdam, Netherlands)

|March 20, 2025

概括

抗血管生成疗法对晚期SMARCA4缺陷胸部瘤 (SDTTs) 显示出前景. 组合治疗包括化疗,抗血管原剂和免疫检查点抑制剂 (ICI) 提供了最长的无进展生存期.

科学领域:

在瘤学瘤学.
胸部瘤学胸部瘤学
癌症治疗方法癌症治疗方法

背景情况:

缺少SMARCA4的胸部瘤 (SDTTs) 通常存在于晚期,预后不佳.
新的治疗策略,特别是抗血管生成疗法,对于改善SDTT患者的治疗结果至关重要.
在SDTT中抗血管原治疗的疗效以前没有被确立.

研究的目的:

评估抗血管生成疗法作为先进SDTTs的第一线治疗的疗效.
为了比较接受抗血管原治疗的SDTT患者和没有接受抗血管原治疗的患者之间的治疗结果.
为了确定高级SDTT的最佳组合疗法.

主要方法:

进行了一项回顾性队列研究,涉及151名晚期SDTT患者.
患者通过免疫组织化学诊断,并在2018年8月至2024年8月期间接受治疗.
在接受抗血管原体疗法 (n=49) 和未接受抗血管原体疗法 (n=102) 的患者之间比较了结局.

主要成果:

与没有抗血管原体疗法相比,抗血管原体疗法显著改善了客观反应率 (ORR) 和疾病控制率 (DCR).
在接受抗血管原治疗的患者中,无进展生存时间 (PFS) 的中位数较长 (7.97个月与5.87个月).
与化疗,抗血管原体剂和ICI (C+I+A) 联合治疗显示,与化疗加抗血管原体治疗 (C+A) 或单独化疗 (C) 相比,PFS持续时间最长 (11.90个月).

结论:

抗血管生成疗法在高级SDTT患者的第一线治疗中显示出有前途的效果.
化疗,抗血管原剂和免疫检查点抑制剂 (C + I + A) 的组合代表了目前用于高级SDTTs的最佳治疗策略.

关键词:

抗血管性疗法是一种抗血管性疗法.化学免疫疗法是一种化学免疫疗法.这就是SMARCA4-dNSCLCLC.这是一个SMARCA4-dUT的标志.缺少SMARCA4的胸部瘤

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...